Date Filed | Type | Description |
06/08/2023 |
4
| STALNECKER SUSAN M (Director) has filed a Form 4 on Bioventus Inc.
Txns:
| Exercised 16,648 restricted stock units
@ $0 Granted 30,400 restricted stock units
@ $0 |
|
05/09/2023 |
4
| STALNECKER SUSAN M (Director) has filed a Form 4 on Leidos Holdings, Inc.
Txns:
| Granted 1,574 shares
@ $0 Granted 2,296 options to buy
@ $79.45, valued at
$182.4k
|
|
06/22/2022 |
4
| STALNECKER SUSAN M (Director) has filed a Form 4 on Bioventus Inc.
Txns:
| Granted 16,648 restricted stock units
@ $0 |
|
05/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/05/2022 |
4
| STALNECKER SUSAN M (Director) has filed a Form 4 on Bioventus Inc.
Txns:
| Exercised 23,416 restricted stock units
@ $0 |
|
02/15/2022 |
4
| STALNECKER SUSAN M (Director) has filed a Form 4 on Bioventus Inc.
Txns:
| Exercised 9,000 restricted stock units
@ $0 |
|
05/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/16/2021 |
4
| STALNECKER SUSAN M (Director) has filed a Form 4 on Bioventus Inc.
Txns:
| Granted 9,000 restricted stock units
@ $0 |
|
02/11/2021 |
3
| STALNECKER SUSAN M (Director) has filed a Form 3 on Bioventus Inc. |
05/12/2020 |
4
| STALNECKER SUSAN M (Director) has filed a Form 4 on Leidos Holdings, Inc.
Txns:
| Granted 1,047 shares
@ $0 |
|
05/14/2019 |
4
| STALNECKER SUSAN M (Director) has filed a Form 4 on Leidos Holdings, Inc.
Txns:
| Granted 1,400 shares
@ $0 Granted 3,345 options to buy
@ $75.02, valued at
$250.9k
|
|
05/15/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/16/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
08/18/2016 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
01/05/2009 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
12/02/2008 |
4
| STALNECKER SUSAN M (Director) has filed a Form 4 on PPL CORP |